Skip to content

Author

Jamal Elkhabchi

We have 1 of 1 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

In Silico Optimization of Dihydropteridine Derivatives Targeting PLK1 for Glioblastoma: An Integrated QSAR, Docking, and Molecular Dynamics Study

Computational findings support the prioritization of X14 for further experimental validation in glioblastoma therapy, and generally favorable ADMET profiles were observed, hepatotoxicity alerts were predicted for all compounds, which represents an important limitation supporting the prioritization of X14.

Youssef Briach, M. Er-rajy, Jamal Elkhabchi et al. · 0 citations